Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1120-1123

  Nguyen, M Hong ^a,b   Najvar, Laura K ^c   Yu, Christine Y ^a   Graybill, John R ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE;

AIDS RELATED COMPLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG MIXTURE; DRUG POTENTIATION; FUNGAL MENINGITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030952922     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1120     Document Type: Article

References (11)

1. Allendoerfer, R., A. J. Marquis, M. G. Rinaldi, and J. R. Graybill. 1991. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 35:726-729.
2. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126-131.
3. Berenbaum, M. D. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.
4. Edelstein, H. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976.
5. Kartalija, M., K. Kaye, J. H. Tureen, Q. Liu, M. G. Tauber, B. R. Elliott, and M. A. Sande. 1996. Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J. Infect. Dis. 173:1216-1221.
6. Larsen, R. A., M. A. E. Leal, and L. S. Chan. 1990. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann. Intern. Med. 113:183-187.
7. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
8. Nguyen, M. H., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
9. Saag, M. S., W. G. Powderly, G. A. Cloud, et al. 1992. Comparison of amphotericin B and fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.
10. Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.
11. Viard, J. P., C. Hennequin, N. Fortineau, N. Pertuiset, C. Rothschild, and H. Zylberberg. 1995. Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole. Lancet 346:118.